A Phase 3 interventional study of Dulaglutide and Oral antihyperglycemics in Diabetes Mellitus, Diabetes Mellitus, Type 2 and Glucose Metabolism Disorders, sponsored by Eli Lilly and Company. Completed at 44 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is the only one that started in 2021, is one of 22 in phase 3, and was the 41st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 591 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 49th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2021, is one of 85 in phase 3, and was the 172nd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 591 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have the following result at screening.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medication (OAM). Participants on dipeptidyl peptidase-4 inhibitors (DPP-4i) discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
Drug: Dulaglutide · Drug: Oral antihyperglycemics
Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
Drug: Dulaglutide · Drug: Oral antihyperglycemics
Administered SC
Also known as: LY2189265
Administered orally
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pre-study oral antihyperglycemic medication (OAM) Group 1 + Treatment + Time + Treatment × Time as variables.
Time frame: Baseline, Week 26
Change From Baseline in HbA1c at Week 52
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.
Time frame: Baseline, Week 52
Percentage of Participants Achieving HbA1c Target ≤6.5% and <7.0%
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The odds ratios, confidence intervals, and p-values were determined by generalized linear mixed model (GLM) with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.
Time frame: Week 52
Change From Baseline in Fasting Serum Glucose (FSG)
FSG is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.
Time frame: Baseline, Week 52
Change From Baseline in 6-point Self-Monitored Blood Glucose (SMBG)
SMBG 6-point profiles were measured at morning (premeal-fasting, 2-hour post meal), midday (premeal, 2-hour post meal), and evening (premeal, 2-hour post meal). LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment as variables.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight
LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.
Time frame: Baseline, Week 52
591 participants were randomized in the study. However, due to good clinical practice (GCP) compliance issues identified at one of the investigative sites, all 5 participants from that site were excluded from the study analyses.
| Milestone | Dulaglutide 1.5 Milligram (mg) | Dulaglutide 0.75 mg |
|---|---|---|
| Started | 395 | 196 |
| Exposed to at least 1 dose of study intervention (excluding the gcp compliance investigative site) | 391 | 195 |
| Completed | 377 | 190 |
| Not completed | 18 | 6 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 9 | 5 |
| Withdrew: Due to long-term overseas business trips | 1 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pre-study oral antihyperglycemic medication (OAM) Group 1 + Treatment + Time + Treatment × Time as variables.
| Percentage of HbA1c | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 | -1.53 ± 0.043 | -1.25 ± 0.060 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.
| Percentage of HbA1c | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Change From Baseline in HbA1c at Week 52 | -1.50 ± 0.046 | -1.19 ± 0.065 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The odds ratios, confidence intervals, and p-values were determined by generalized linear mixed model (GLM) with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.
| Percentage of participants | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| HbA1c ≤ 6.5% | 22.88 | 21.26 |
| HbA1c < 7% | 46.33 | 38.51 |
FSG is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.
| milligrams per deciliter (mg/dL) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -42.4 ± 1.47 | -33.1 ± 2.09 |
SMBG 6-point profiles were measured at morning (premeal-fasting, 2-hour post meal), midday (premeal, 2-hour post meal), and evening (premeal, 2-hour post meal). LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment as variables.
| mg/dL | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Morning premeal-fasting | -45.6 ± 1.33 | -38.4 ± 1.86 |
| Morning 2-hour post meal | -70.6 ± 2.42 | -60.5 ± 3.39 |
| Midday premeal | -55.3 ± 1.77 | -47.0 ± 2.47 |
| Midday 2-hour post meal | -73.7 ± 2.37 | -61.2 ± 3.32 |
| Evening premeal | -50.3 ± 1.60 | -46.4 ± 2.24 |
| Evening 2-hour post meal | -61.1 ± 2.27 | -49.8 ± 3.18 |
LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.
| kilogram (kg) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Change From Baseline in Body Weight | -0.5 ± 0.14 | -0.2 ± 0.19 |
Collected over Baseline to Week 56.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dulaglutide 1.5 mg | 1/391 (0.3%) | 15/391 (3.8%) | 298/391 (76.2%) |
| Dulaglutide 0.75 mg | 0/195 (0%) | 7/195 (3.6%) | 143/195 (73.3%) |
| Event | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| Cervix carcinoma stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/113 | 0/53 |
| Angina pectorisCardiac disorders | 0/391 | 1/195 |
| Retinal haemorrhageEye disorders | 0/391 | 1/195 |
| Vitreous haemorrhageEye disorders | 0/391 | 1/195 |
| Colitis ischaemicGastrointestinal disorders | 0/391 | 1/195 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/391 | 1/195 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/391 | 1/195 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/391 | 1/195 |
| Acute myocardial infarctionCardiac disorders | 1/391 | 0/195 |
| Cardiac failure congestiveCardiac disorders | 1/391 | 0/195 |
| Event | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg |
|---|---|---|
| ConstipationGastrointestinal disorders | 49/391 | 17/195 |
| DiarrhoeaGastrointestinal disorders | 40/391 | 16/195 |
| PyrexiaGeneral disorders | 39/391 | 14/195 |
| NauseaGastrointestinal disorders | 35/391 | 9/195 |
| NasopharyngitisInfections and infestations | 22/391 | 17/195 |
| Covid-19Infections and infestations | 30/391 | 16/195 |
| Abdominal discomfortGastrointestinal disorders | 24/391 | 5/195 |
| Coronavirus infectionInfections and infestations | 18/391 | 8/195 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/391 | 8/195 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/391 | 8/195 |
All randomly assigned participants, excluding the GCP compliance investigative site, who were exposed to at least 1 dose of study intervention.
| Age, Continuous(years) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg | Total |
|---|---|---|---|
| Mean | 60.10 ± 10.70 | 60.70 ± 10.74 | 60.30 ± 10.71 |
| Sex: Female, Male(Participants) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg | Total |
|---|---|---|---|
| Female | 113 | 53 | 166 |
| Male | 278 | 142 | 420 |
| Race (NIH/OMB)(Participants) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 391 | 195 | 586 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg | Total |
|---|---|---|---|
| Japan | 391 | 195 | 586 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | Dulaglutide 1.5 mg | Dulaglutide 0.75 mg | Total |
|---|---|---|---|
| Mean | 8.61 ± 0.62 | 8.61 ± 0.60 | 8.61 ± 0.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Oct 2022, 17 months.
Results were first posted in Sep 2023, 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide